Nanoparticle Albumin Bound Paclitaxel in the Treatment of Human Cancer: Nanodelivery Reaches Prime-Time? | Zendy

Iole Cucinotto | Zendy; Lucia Fiorillo | Zendy; S Gualtieri | Zendy; Mariamena Arbitrio | Zendy; Domenico Ciliberto | Zendy; Nicoletta Staropoli | Zendy; Anna Grimaldi | Zendy; Amalia Luce | Zendy; Pierfrancesco Tassone | Zendy; Michele Caraglia | Zendy; Pierosandro Tagliaferri | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Nanoparticle Albumin Bound Paclitaxel in the Treatment of Human Cancer: Nanodelivery Reaches Prime-Time?

Author(s) -

Iole Cucinotto,

Lucia Fiorillo,

S Gualtieri,

Mariamena Arbitrio,

Domenico Ciliberto,

Nicoletta Staropoli,

Anna Grimaldi,

Amalia Luce,

Pierfrancesco Tassone,

Michele Caraglia,

Pierosandro Tagliaferri

Publication year - 2013

Publication title -

journal of drug delivery

Language(s) - English

Resource type - Journals

eISSN - 2090-3014

pISSN - 2090-3022

DOI - 10.1155/2013/905091

Subject(s) - paclitaxel , taxane , pancreatic cancer , cancer , drug , albumin , medicine , human breast , pharmacology , toxicity , human serum albumin , refractory (planetary science) , breast cancer , chemistry , biology , biochemistry , astrobiology

Nanoparticle albumin bound paclitaxel (nab-paclitaxel) represents the first nanotechnology-based drug in cancer treatment. We discuss the development of this innovative compound and report the recent changing-practice results in breast and pancreatic cancer. A ground-breaking finding is the demonstration that nab-paclitaxel can not only enhance the activity and reduce the toxicity of chromophore-diluted compound, but also exert activity in diseases considered refractory to taxane-based treatment. This is the first clinical demonstration of major activity of nanotechnologically modified drugs in the treatment of human neoplasms.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research